Barcelona
,
Spain
9 - 12 May 2026
Heart Failure 2026 (ESC-HFA 2026)
Presentation schedule and materials
Sunday, 10 May 2026
13:51
- 14:00
CEST
ORAL PRESENTATION
Efficacy and safety of the microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT)
Johann Bauersachs1; Scott D Solomon 2; Stefan D Anker 3; Isabel Antorrena-Miranda 4; Rudolf A de Boer 5; Gerasimos Filippatos 6; Tim Friede 7; Wilfried Hauke 8; Piotr Ponikowski 9; Orly Vardeny 10; Rebecca Altschul 11; Michael Gamborg 11; Kasper Vinther 11; Thomas Thum 8
MATERIALS AVAILABLE
14:48
- 14:57
CEST
ORAL PRESENTATION
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Guiomar Mendieta Badimon 1; Paul M. Ridker 2; Pernille Auerbach 3; Barry A. Borlaug 4; Maja Cikes 5; Anique Ducharme 6; Marat Fudim 7; Anders Hvelplund 3; Carolyn S.P. Lam 8; Marie Mide Michelsen 3; Adriaan A. Voors 9; Mark C Petrie 10
MATERIALS AVAILABLE
16:18
- 16:30
CEST
ORAL PRESENTATION
Prevalence of high inflammatory risk in heart failure across the ejection fraction spectrum: Findings From the Global POSEIDON Study
Carolyn SP Lam 1; Johanna Contreras 2; Raed Darwesh 3; Aguinaldo F Freitas Junior 4; Søren Lund Kristensen 3; Koichiro Kuwahara 5; Andrew J Ludman 6; Ma Changsheng 7; Nikolaus Marx 8; Jimmi Mathisen 3; Ann Marie Navar 9; Adam J Nelson 10; Matteo Pirro 11; Shelley Zieroth 12; Adriaan A Voors 13
MATERIALS AVAILABLE
Keywords